Mauro Delorenzi

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil

155 publications

2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 1990 | 1988 | 1986 |
TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection.
Alfei F., Kanev K., Hofmann M., Wu M., Ghoneim H.E., Roelli P., Utzschneider D.T., von Hoesslin M., Cullen J.G., Fan Y. et al., 2019/07. Nature, 571 (7764) pp. 265-269. Peer-reviewed.
RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer.
Gbenedio O.M., Bonnans C., Grun D., Wang C.Y., Hatch A.J., Mahoney M.R., Barras D., Matli M., Miao Y., Garcia K.C. et al., 2019/06/25. JCI insight, 5. Peer-reviewed.
Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors.
Dangaj D., Bruand M., Grimm A.J., Ronet C., Barras D., Duttagupta P.A., Lanitis E., Duraiswamy J., Tanyi J.L., Benencia F. et al., 2019/06/10. Cancer cell, 35 (6) pp. 885-900.e10. Peer-reviewed.
Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer.
Lan Q., Peyvandi S., Duffey N., Huang Y.T., Barras D., Held W., Richard F., Delorenzi M., Sotiriou C., Desmedt C. et al., 2019/04. Oncogene, 38 (15) pp. 2814-2829. Peer-reviewed.
Differential regulation of RNA polymerase III genes during liver regeneration.
Yeganeh M., Praz V., Carmeli C., Villeneuve D., Rib L., Guex N., Herr W., Delorenzi M., Hernandez N., CycliX consortium, 2019/02/28. Nucleic Acids Research, 47 (4) pp. 1786-1796. Peer-reviewed.
Endothelial Calcineurin Signaling Restrains Metastatic Outgrowth by Regulating Bmp2.
Hendrikx S., Coso S., Prat-Luri B., Wetterwald L., Sabine A., Franco C.A., Nassiri S., Zangger N., Gerhardt H., Delorenzi M. et al., 2019/01/29. Cell reports, 26 (5) pp. 1227-1241.e6. Peer-reviewed.
Comprehensive Genomic Profiling of Patient-matched Head and Neck Cancer Cells: A Preclinical Pipeline for Metastatic and Recurrent Disease.
Nisa L., Barras D., Medová M., Aebersold D.M., Medo M., Poliaková M., Koch J., Bojaxhiu B., Eliçin O., Dettmer M.S. et al., 2018/12. Molecular cancer research, 16 (12) pp. 1912-1926. Peer-reviewed.
Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial.
Tejpar S., Yan P., Piessevaux H., Dietrich D., Brauchli P., Klingbiel D., Fiocca R., Delorenzi M., Bosman F., Roth A.D., 2018/08. European journal of cancer, 99 pp. 66-77. Peer-reviewed.
The transcription factor Rfx7 limits metabolism of NK cells and promotes their maintenance and immunity.
Castro W., Chelbi S.T., Niogret C., Ramon-Barros C., Welten SPM, Osterheld K., Wang H., Rota G., Morgado L., Vivier E. et al., 2018/08. Nature immunology, 19 (8) pp. 809-820. Peer-reviewed.
The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033.
Bady P., Kurscheid S., Delorenzi M., Gorlia T., van den Bent M.J., Hoang-Xuan K., Vauléon É., Gijtenbeek A., Enting R., Thiessen B. et al., 2018/04. Acta neuropathologica, 135 (4) pp. 601-615. Peer-reviewed.
Modulation of the peripheral blood transcriptome by the ingestion of probiotic yoghurt and acidified milk in healthy, young men.
Burton K.J., Pimentel G., Zangger N., Vionnet N., Drai J., McTernan P.G., Pralong F.P., Delorenzi M., Vergères G., 2018. PloS one, 13 (2) pp. e0192947. Peer-reviewed.
Mutant <i>CTNNB1</i> and histological heterogeneity define metabolic subtypes of hepatoblastoma.
Crippa S., Ancey P.B., Vazquez J., Angelino P., Rougemont A.L., Guettier C., Zoete V., Delorenzi M., Michielin O., Meylan E., 2017/11. EMBO molecular medicine, 9 (11) pp. 1589-1604. Peer-reviewed.
RIP4 inhibits STAT3 signaling to sustain lung adenocarcinoma differentiation.
Kopparam J., Chiffelle J., Angelino P., Piersigilli A., Zangger N., Delorenzi M., Meylan E., 2017/10. Cell death and differentiation, 24 (10) pp. 1761-1771. Peer-reviewed.
The Transcription Factor Tcf1 Contributes to Normal NK Cell Development and Function by Limiting the Expression of Granzymes.
Jeevan-Raj B., Gehrig J., Charmoy M., Chennupati V., Grandclément C., Angelino P., Delorenzi M., Held W., 2017/07/18. Cell reports, 20 (3) pp. 613-626. Peer-reviewed.
Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial.
Aalders K.C., Kuijer A., Straver M.E., Slaets L., Litiere S., Viale G., Van't Veer L.J., Glas A.M., Delorenzi M., van Dalen T. et al., 2017/07. European journal of cancer, 79 pp. 98-105. Peer-reviewed.
Increased ex vivo antigen presentation profile of B cells in multiple sclerosis.
Mathias A., Perriard G., Canales M., Soneson C., Delorenzi M., Schluep M., Du Pasquier R.A., 2017/05. Multiple sclerosis, 23 (6) pp. 802-809. Peer-reviewed.
Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study.
Dienstmann R., Mason M.J., Sinicrope F.A., Phipps A.I., Tejpar S., Nesbakken A., Danielsen S.A., Sveen A., Buchanan D.D., Clendenning M. et al., 2017/05/01. Annals of oncology, 28 (5) pp. 1023-1031. Peer-reviewed.
Broad and Conserved Immune Regulation by Genetically Heterogeneous Melanoma Cells.
Neubert N.J., Tillé L., Barras D., Soneson C., Baumgaertner P., Rimoldi D., Gfeller D., Delorenzi M., Fuertes Marraco S.A., Speiser D.E., 2017/04/01. Cancer research, 77 (7) pp. 1623-1636. Peer-reviewed.
Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin.
Dobay M.P., Lemonnier F., Missiaglia E., Bastard C., Vallois D., Jais J.P., Scourzic L., Dupuy A., Fataccioli V., Pujals A. et al., 2017/04. Haematologica, 102 (4) pp. e148-e151. Peer-reviewed.
Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.
Frismantas V., Dobay M.P., Rinaldi A., Tchinda J., Dunn S.H., Kunz J., Richter-Pechanska P., Marovca B., Pail O., Jenni S. et al., 2017/03/16. Blood, 129 (11) pp. e26-e37. Peer-reviewed.
BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression.
Barras D., Missiaglia E., Wirapati P., Sieber O.M., Jorissen R.N., Love C., Molloy P.L., Jones I.T., McLaughlin S., Gibbs P. et al., 2017/01/01. Clinical cancer research, 23 (1) pp. 104-115. Peer-reviewed.
Caloric dose-responsive genes in blood cells differentiate the metabolic status of obese men.
Gille D., Zangger N., Soneson C., Bütikofer U., Delorenzi M., Schwander F., Kopf-Bolanz K.A., Chollet M., Walther B., Laederach K. et al., 2017. The Journal of Nutritional Biochemistry, 43 pp. 156-165. Peer-reviewed.
Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.
Domingo E., Freeman-Mills L., Rayner E., Glaire M., Briggs S., Vermeulen L., Fessler E., Medema J.P., Boot A., Morreau H. et al., 2016/11. The lancet. Gastroenterology & hepatology, 1 (3) pp. 207-216. Peer-reviewed.
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
Cardoso F., van't Veer L.J., Bogaerts J., Slaets L., Viale G., Delaloge S., Pierga J.Y., Brain E., Causeret S., DeLorenzi M. et al., 2016/08/25. The New England journal of medicine, 375 (8) pp. 717-729. Peer-reviewed.
High antigen levels induce an exhausted phenotype in a chronic infection without impairing T cell expansion and survival.
Utzschneider D.T., Alfei F., Roelli P., Barras D., Chennupati V., Darbre S., Delorenzi M., Pinschewer D.D., Zehn D., 2016/08/22. The Journal of experimental medicine, 213 (9) pp. 1819-1834. Peer-reviewed.
A Well-Controlled Experimental System to Study Interactions of Cytotoxic T Lymphocytes with Tumor Cells.
Neubert N.J., Soneson C., Barras D., Baumgaertner P., Rimoldi D., Delorenzi M., Fuertes Marraco S.A., Speiser D.E., 2016/08. Frontiers In Immunology, 7 p. 326. Peer-reviewed.
Reduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer.
Yan P., Klingbiel D., Saridaki Z., Ceppa P., Curto M., McKee T.A., Roth A., Tejpar S., Delorenzi M., Bosman F.T. et al., 2016/06/15. Clinical cancer research, 22 (12) pp. 3037-3047. Peer-reviewed.
A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome.
Schell M.J., Yang M., Missiaglia E., Delorenzi M., Soneson C., Yue B., Nebozhyn M.V., Loboda A., Bloom G., Yeatman T.J., 2016. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research, 22 (3) pp. 734-745. Peer-reviewed.
A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility.
Vecchione L., Gambino V., Raaijmakers J., Schlicker A., Fumagalli A., Russo M., Villanueva A., Beerling E., Bartolini A., Mollevi D.G. et al., 2016. Cell, 165 (2) pp. 317-330. Peer-reviewed.
Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas.
Vallois D., Dobay M.P., Morin R.D., Lemonnier F., Missiaglia E., Juilland M., Iwaszkiewicz J., Fataccioli V., Bisig B., Roberti A. et al., 2016. Blood, 128 (11) pp. 1490-1502.
Cell Line Derived 5-FU and Irinotecan Drug-Sensitivity Profiles Evaluated in Adjuvant Colon Cancer Trial Data.
Buhl I.K., Gerster S., Delorenzi M., Jensen T., Jensen P.B., Bosman F., Tejpar S., Roth A., Brunner N., Hansen A. et al., 2016. PloS one, 11 (5) pp. e0155123. Peer-reviewed.
Comparison between direct and reverse electroporation of cells in situ: a simulation study.
Towhidi L., Khodadadi D., Maimari N., Pedrigi R.M., Ip H., Kis Z., Kwak B.R., Petrova T.W., Delorenzi M., Krams R., 2016. Physiological Reports, 4 (6) pp. e12673. Peer-reviewed.
DNA Topoisomerase I Gene Copy Number and mRNA Expression Assessed as Predictive Biomarkers for Adjuvant Irinotecan in Stage II/III Colon Cancer.
Nygård S.B., Vainer B., Nielsen S.L., Bosman F., Tejpar S., Roth A., Delorenzi M., Brünner N., Budinska E., 2016. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research, 22 (7) pp. 1621-1631. Peer-reviewed.
Modulation of mTOR Signalling Triggers the Formation of Stem Cell-like Memory T Cells.
Scholz G., Jandus C., Zhang L., Grandclément C., Lopez-Mejia I.C., Soneson C., Delorenzi M., Fajas L., Held W., Dormond O. et al., 2016. Ebiomedicine, 4 pp. 50-61. Peer-reviewed.
Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors.
Bady P., Delorenzi M., Hegi M.E., 2016. Journal of Molecular Diagnostics, 18 (3) pp. 350-361. Peer-reviewed.
BCL9/9L-β-catenin Signaling is Associated With Poor Outcome in Colorectal Cancer.
Moor A.E., Anderle P., Cantù C., Rodriguez P., Wiedemann N., Baruthio F., Deka J., André S., Valenta T., Moor M.B. et al., 2015. Ebiomedicine, 2 (12) pp. 1932-1943. Peer-reviewed.
Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma.
Kurscheid S., Bady P., Sciuscio D., Samarzija I., Shay T., Vassallo I., Criekinge W.V., Daniel R.T., van den Bent M.J., Marosi C. et al., 2015. Genome Biology, 16 (1) p. 16. Peer-reviewed.
Clinical Application of Prognostic Gene Expression Signature in Fusion Gene-Negative Rhabdomyosarcoma: A Report from the Children's Oncology Group.
Hingorani P., Missiaglia E., Shipley J., Anderson J.R., Triche T.J., Delorenzi M., Gastier-Foster J., Wing M., Hawkins D.S., Skapek S.X., 2015. Clinical Cancer Research, 21 (20) pp. 4733-4739. Peer-reviewed.
FOXC2 and fluid shear stress stabilize postnatal lymphatic vasculature.
Sabine A., Bovay E., Demir C.S., Kimura W., Jaquet M., Agalarov Y., Zangger N., Scallan J.P., Graber W., Gulpinar E. et al., 2015. Journal of Clinical Investigation, 125 (10) pp. 3861-3877. Peer-reviewed.
Genome-wide DNA methylation detection by MethylCap-seq and Infinium HumanMethylation450 BeadChips: an independent large-scale comparison.
De Meyer T., Bady P., Trooskens G., Kurscheid S., Bloch J., Kros J.M., Hainfellner J.A., Stupp R., Delorenzi M., Hegi M.E. et al., 2015. Scientific Reports, 5 p. 15375. Peer-reviewed.
Genome-wide RNA profiling of long-lasting stem cell-like memory CD8 T cells induced by Yellow Fever vaccination in humans.
Fuertes Marraco S.A., Soneson C., Delorenzi M., Speiser D.E., 2015. Genomics Data, 5 pp. 297-301. Peer-reviewed.
Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options.
Fischer U., Forster M., Rinaldi A., Risch T., Sungalee S., Warnatz H.J., Bornhauser B., Gombert M., Kratsch C., Stütz A.M. et al., 2015. Nature Genetics, 47 (9) pp. 1020-1029. Peer-reviewed.
Long-lasting stem cell-like memory CD8+ T cells with a naïve-like profile upon yellow fever vaccination.
Fuertes Marraco S.A., Soneson C., Cagnon L., Gannon P.O., Allard M., Maillard S.A., Montandon N., Rufer N., Waldvogel S., Delorenzi M. et al., 2015. Science Translational Medicine, 7 (282) pp. 282ra48. Peer-reviewed.
Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial?.
Klingbiel D., Saridaki Z., Roth A.D., Bosman F.T., Delorenzi M., Tejpar S., 2015. Annals of Oncology, 26 (1) pp. 126-132. Peer-reviewed.
The consensus molecular subtypes of colorectal cancer.
Guinney J., Dienstmann R., Wang X., de Reyniès A., Schlicker A., Soneson C., Marisa L., Roepman P., Nyamundanda G., Angelino P. et al., 2015. Nature Medicine, 21 (11) pp. 1350-1356. Peer-reviewed.
A novel bioinformatics pipeline to discover genes related to arbuscular mycorrhizal symbiosis based on their evolutionary conservation pattern among higher plants.
Favre P., Bapaume L., Bossolini E., Delorenzi M., Falquet L., Reinhardt D., 2014. Bmc Plant Biology, 14 (1) p. 333. Peer-reviewed.
Batch effect confounding leads to strong bias in performance estimates obtained by cross-validation.
Soneson C., Gerster S., Delorenzi M., 2014. Plos One, 9 (6) pp. e100335. Peer-reviewed.
Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy.
Sistigu A., Yamazaki T., Vacchelli E., Chaba K., Enot D.P., Adam J., Vitale I., Goubar A., Baracco E.E., Remédios C. et al., 2014. Nature Medicine, 20 (11) pp. 1301-1309. Peer-reviewed.
Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features.
Missiaglia E., Jacobs B., D'Ario G., Di Narzo A.F., Soneson C., Budinska E., Popovici V., Vecchione L., Gerster S., Yan P. et al., 2014. Annals of Oncology, 25 (10) pp. 1995-2001. Peer-reviewed.
Fifteen years SIB Swiss Institute of Bioinformatics: life science databases, tools and support.
Stockinger H., Altenhoff A.M., Arnold K., Bairoch A., Bastian F., Bergmann S., Bougueleret L., Bucher P., Delorenzi M., Lane L. et al., 2014. Nucleic Acids Research, 42 (Web Server issue) pp. W436-W441. Peer-reviewed.
Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels.
Bossard C., Dobay M.P., Parrens M., Lamant L., Missiaglia E., Haioun C., Martin A., Fabiani B., Delarue R., Tournilhac O. et al., 2014. Blood, 124 (19) pp. 2983-2986. Peer-reviewed.
miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan.
Schou J.V., Rossi S., Jensen B.V., Nielsen D.L., Pfeiffer P., Høgdall E., Yilmaz M., Tejpar S., Delorenzi M., Kruhøffer M. et al., 2014. Plos One, 9 (6) pp. e99886. Peer-reviewed.
PROX1 Promotes Metabolic Adaptation and Fuels Outgrowth of Wnt(high) Metastatic Colon Cancer Cells.
Ragusa S., Cheng J., Ivanov K.I., Zangger N., Ceteci F., Bernier-Latmani J., Milatos S., Joseph J.M., Tercier S., Bouzourene H. et al., 2014. Cell Reports, 8 (6) pp. 1957-1973. Peer-reviewed.
Quantifying ChIP-seq data: a spiking method providing an internal reference for sample-to-sample normalization.
Bonhoure N., Bounova G., Bernasconi D., Praz V., Lammers F., Canella D., Willis I.M., Herr W., Hernandez N., Delorenzi M. et al., 2014. Genome Research, 24 (7) pp. 1157-1168.
Test of four colon cancer risk-scores in formalin fixed paraffin embedded microarray gene expression data.
Di Narzo A.F., Tejpar S., Rossi S., Yan P., Popovici V., Wirapati P., Budinska E., Xie T., Estrella H., Pavlicek A. et al., 2014. Journal of the National Cancer Institute, 106 (10) pp. 1-8.
The Hippo Transducer YAP1 Transforms Activated Satellite Cells and Is a Potent Effector of Embryonal Rhabdomyosarcoma Formation.
Tremblay A.M., Missiaglia E., Galli G.G., Hettmer S., Urcia R., Carrara M., Judson R.N., Thway K., Nadal G., Selfe J.L. et al., 2014. Cancer Cell, 26 (2) pp. 273-287. Peer-reviewed.
The molecular signature of the stroma response in prostate cancer-induced osteoblastic bone metastasis highlights expansion of hematopoietic and prostate epithelial stem cell niches.
Özdemir B.C., Hensel J., Secondini C., Wetterwald A., Schwaninger R., Fleischmann A., Raffelsberger W., Poch O., Delorenzi M., Temanni R. et al., 2014. Plos One, 9 (12) pp. e114530. Peer-reviewed.
Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer.
Popovici V., Budinska E., Bosman F.T., Tejpar S., Roth A.D., Delorenzi M., 2013/09/27. BMC cancer, 13 p. 439. Peer-reviewed.
3522: BRAF and KRAS mutations as additional risk factors in the context of clinical parameters of patients with colorectal cancer.
Popovici VC, Budinska E., Roth A., Bosman F., Tejpar S., Delorenzi M., 2013. p. 3522 dans Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Journal of Clinical Oncology.
3526: Proximal and distal colon tumors as distinct biologic entities with different prognoses.
Missiaglia E., Jacobs B., Di Narzo AF, Soneson C., Roth A., Bosman F., D'Ario G., Klingbiel D., Yan P., Delorenzi M. et al., 2013. p. 3526 dans Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Journal of Clinical Oncology.
3577: Thymidylate synthase (TS) expression as a prognostic molecular marker in stage II/III colon cancer.
Klingbiel D., Missiaglia E., Yan P., Tejpar S., Roth A., D'Ario G., Delorenzi M., Bosman F., 2013. p. 3577 dans Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Journal of Clinical Oncology.
A comparison of methods for differential expression analysis of RNA-seq data.
Soneson C., Delorenzi M., 2013. BMC Bioinformatics, 14 p. 91.
DUSP 4 expression identifies a subset of colorectal cancer tumors that differ in MAPK activation, regardless of the genotype.
De Vriendt V., De Roock W., Di Narzo A.F., Tian S., Biesmans B., Jacobs B., Budinska E., Sagaert X., Rossi S., D'Ario G. et al., 2013. Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility To Chemicals, 18 (6) pp. 516-524.
e14544: Connecting gene expression subtypes of colorectal cancer (CRC) with cell lines and drug resistance
Budinska E., Wilding J., Popovici VC, Missiaglia E., Roth A., Bosman F., Delorenzi M., Bodmer W., Tejpar S., 2013. pp. e14544 dans Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Journal of Clinical Oncology. Peer-reviewed.
Erratum to: MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.
Bady P., Sciuscio D., Diserens A.C., Bloch J., van den Bent M.J., Marosi C., Dietrich P.Y., Weller M., Mariani L., Heppner F.L. et al., 2013. Acta Neuropathologica, 126 (1) p. 159.
Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer.
Budinska E., Popovici V., Tejpar S., D'Ario G., Lapique N., Sikora K.O., Di Narzo A.F., Yan P., Hodgson J.G., Weinrich S. et al., 2013. Journal of Pathology, 231 (1) pp. 63-76. Peer-reviewed.
Phosphorylation regulates FOXC2-mediated transcription in lymphatic endothelial cells.
Ivanov K.I., Agalarov Y., Valmu L., Samuilova O., Liebl J., Houhou N., Maby-El Hajjami H., Norrmén C., Jaquet M., Miura N. et al., 2013. Molecular and Cellular Biology, 33 (19) pp. 3749-3761.
A comprehensive characterization of genome-wide copy number aberrations in colorectal cancer reveals novel oncogenes and patterns of alterations.
Xie T., D' Ario G., Lamb J.R., Martin E., Wang K., Tejpar S., Delorenzi M., Bosman F.T., Roth A.D., Yan P. et al., 2012. PLoS One, 7 (7) pp. e42001. Peer-reviewed.
A multiplicity of factors contributes to selective RNA polymerase III occupancy of a subset of RNA polymerase III genes in mouse liver.
Canella D., Bernasconi D., Gilardi F., LeMartelot G., Migliavacca E., Praz V., Cousin P., Delorenzi M., Hernandez N., CycliX Consortium, 2012. Genome Research, 22 (4) pp. 666-680.
A robust genomic signature for the detection of colorectal cancer patients with microsatellite instability phenotype and high mutation frequency.
Tian S., Roepman P., Popovici V., Michaut M., Majewski I., Salazar R., Santos C., Rosenberg R., Nitsche U., Mesker W.E. et al., 2012. Journal of Pathology, 228 (4) pp. 586-595.
Breast cancer suppressor candidate-1 (BCSC-1) is a melanoma tumor suppressor that down regulates MITF.
Anghel S.I., Correa-Rocha R., Correa-Rochal R., Budinska E., Boligan K.F., Boliganl K.F., Abraham S., Colombetti S., Fontao L., Mariotti A. et al., 2012. Pigment Cell and Melanoma Research, 25 (4) pp. 482-487.
Characterization and clinical evaluation of CD10+ stroma cells in the breast cancer microenvironment.
Desmedt C., Majjaj S., Kheddoumi N., Singhal S.K., Haibe-Kains B., El Ouriaghli F., Chaboteaux C., Michiels S., Lallemand F., Journe F. et al., 2012. Clinical Cancer Research, 18 (4) pp. 1004-1014. Peer-reviewed.
Defining new criteria for selection of cell-based intestinal models using publicly available databases.
Christensen J., El-Gebali S., Natoli M., Sengstag T., Delorenzi M., Bentz S., Bouzourene H., Rumbo M., Felsani A., Siissalo S. et al., 2012. BMC Genomics, 13 p. 274.
DNA fingerprinting of glioma cell lines and considerations on similarity measurements.
Bady P., Diserens A.C., Castella V., Kalt S., Heinimann K., Hamou M.F., Delorenzi M., Hegi M.E., 2012. Neuro-Oncology, 14 (6) pp. 701-711.
Genetic structure and admixture of the Seychelles' population.
Bady Pierre, Ehret Georg, Shamlaye Conrad, Burnier Michel, Mach Francois, Paccaud Fred, Delorenzi Mauro, Bovet Pascal, Bochud Murielle, 2012. pp. 170-170 dans 20th Annual Conference of the International Genetic Epidemiology Society (IGES 2011), Heidelberg, Germany, September 18-20, 2011, Genetic Epidemiology. Peer-reviewed.
Genome-wide RNA polymerase II profiles and RNA accumulation reveal kinetics of transcription and associated epigenetic changes during diurnal cycles.
Le Martelot G., Canella D., Symul L., Migliavacca E., Gilardi F., Liechti R., Martin O., Harshman K., Delorenzi M., Desvergne B. et al., 2012. PLoS Biology, 10 (11) pp. e1001442.
Genome-wide RNA polymerase II profiles and RNA accumulation reveal kinetics of transcription and associated epigenetic changes during diurnal cycles.
Le Martelot G., Canella D., Symul L., Migliavacca E., Gilardi F., Liechti R., Martin O., Harshman K., Delorenzi M., Desvergne B. et al., 2012. Plos Biology, 10 (11) pp. e1001442.
Identification of a Poor-Prognosis BRAF-Mutant-Like Population of Patients With Colon Cancer.
Popovici V., Budinska E., Tejpar S., Weinrich S., Estrella H., Hodgson G., Van Cutsem E., Xie T., Bosman F.T., Roth A.D. et al., 2012. Journal of Clinical Oncology, 30 (12) pp. 1288-1295.
Identification of MAGI1 as a tumor-suppressor protein induced by cyclooxygenase-2 inhibitors in colorectal cancer cells.
Zaric J., Joseph J.M., Tercier S., Sengstag T., Ponsonnet L., Delorenzi M., Rüegg C., 2012. Oncogene, 31 (1) pp. 48-59.
Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer.
Roth A.D., Delorenzi M., Tejpar S., Yan P., Klingbiel D., Fiocca R., d'Ario G., Cisar L., Labianca R., Cunningham D. et al., 2012. Journal of the National Cancer Institute, 104 (21) pp. 1635-1646.
MFG-E8/lactadherin regulates cyclins D1/D3 expression and enhances the tumorigenic potential of mammary epithelial cells.
Carrascosa C., Obula R.G., Missiaglia E., Lehr H.A., Delorenzi M., Frattini M., Rüegg C., Mariotti A., 2012. Oncogene, 31 (12) pp. 1521-1532.
MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.
Bady P., Sciuscio D., Diserens A.C., Bloch J., van den Bent M.J., Marosi C., Dietrich P.Y., Weller M., Mariani L., Heppner F.L. et al., 2012. Acta Neuropathologica, 124 (4) pp. 547-560. Peer-reviewed.
microRNAs in colon cancer: a roadmap for discovery.
Rossi S., Di Narzo A.F., Mestdagh P., Jacobs B., Bosman F.T., Gustavsson B., Majoie B., Roth A., Vandesompele J., Rigoutsos I. et al., 2012. Febs Letters, 586 (19) pp. 3000-3007.
New frontiers in therapeutic resistance in cancer.
Sartore-Bianchi A., Delorenzi M., Gagnon-Kugler T., Rousseau C., Batist G., 2012. Expert Review of Anticancer Therapy, 12 (7) pp. 877-879.
PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.
Missiaglia E., Williamson D., Chisholm J., Wirapati P., Pierron G., Petel F., Concordet J.P., Thway K., Oberlin O., Pritchard-Jones K. et al., 2012. Journal of Clinical Oncology, 30 (14) pp. 1670-1677. Peer-reviewed.
Detecting epistasis with restricted response patterns in pairs of biallelic loci.
Wirapati P., Forner K., Delgado-Vega A., Alarcón-Riquelme M., Delorenzi M., Wojcik J., 2011. Annals of Human Genetics, 75 (1) pp. 133-145. Peer-reviewed.
Identification of prognostic molecular features in the reactive stroma of human breast and prostate cancer.
Planche A., Bacac M., Provero P., Fusco C., Delorenzi M., Stehle J.C., Stamenkovic I., 2011. Plos One, 6 (5) pp. e18640.
Microsatellite instability, prognosis and drug sensitivity of stage II and III colorectal cancer: more complexity to the puzzle.
Tejpar S., Saridaki Z., Delorenzi M., Bosman F., Roth A.D., 2011. Journal of the National Cancer Institute, 103 (11) pp. 841-844. Peer-reviewed.
Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial.
Hegi M.E., Diserens A.C., Bady P., Kamoshima Y., Kouwenhoven M.C., Delorenzi M., Lambiv W.L., Hamou M.F., Matter M.S., Koch A. et al., 2011. Molecular Cancer Therapeutics, 10 (6) pp. 1102-1112.
Rgtsp: a generalized top scoring pairs package for class prediction.
Popovici V., Budinská E., Delorenzi M., 2011. Bioinformatics, 27 (12) pp. 1729-1730. Peer-reviewed.
The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence.
Lambiv W.L., Vassallo I., Delorenzi M., Shay T., Diserens A.C., Misra A., Feuerstein B., Murat A., Migliavacca E., Hamou M.F. et al., 2011. Neuro-Oncology, 13 (7) pp. 736-747. Peer-reviewed.
Bcl9/Bcl9l are critical for Wnt-mediated regulation of stem cell traits in colon epithelium and adenocarcinomas.
Deka J., Wiedemann N., Anderle P., Murphy-Seiler F., Bultinck J., Eyckerman S., Stehle J.C., André S., Vilain N., Zilian O. et al., 2010. Cancer Research, 70 (16) pp. 6619-6628.
Effect of training-sample size and classification difficulty on the accuracy of genomic predictors.
Popovici V., Chen W., Gallas B.G., Hatzis C., Shi W., Samuelson F.W., Nikolsky Y., Tsyganova M., Ishkin A., Nikolskaya T. et al., 2010. Breast Cancer Research, 12 (1) pp. R5. Peer-reviewed.
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
De Roock W., Claes B., Bernasconi D., De Schutter J., Biesmans B., Fountzilas G., Kalogeras K.T., Kotoula V., Papamichael D., Laurent-Puig P. et al., 2010. Lancet Oncology, 11 (8) pp. 753-762. Peer-reviewed.
Functional analysis: evaluation of response intensities--tailoring ANOVA for lists of expression subsets.
Berger F., De Meulder B., Gaigneaux A., Depiereux S., Bareke E., Pierre M., De Hertogh B., Delorenzi M., Depiereux E., 2010. BMC Bioinformatics, 11 p. 510. Peer-reviewed.
Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue.
Antonov J., Popovici V., Delorenzi M., Wirapati P., Baltzer A., Oberli A., Thürlimann B., Giobbie-Hurder A., Viale G., Altermatt H.J. et al., 2010. BMC Cancer, 10 p. 37. Peer-reviewed.
Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery.
Tejpar S., Bertagnolli M., Bosman F., Lenz H.J., Garraway L., Waldman F., Warren R., Bild A., Collins-Brennan D., Hahn H. et al., 2010. The oncologist, 15 (4) pp. 390-404. Peer-reviewed.
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.
Roth Arnaud D., Tejpar Sabine, Delorenzi Mauro, Yan Pu, Fiocca Roberto, Klingbiel Dirk, Dietrich Daniel, Biesmans Bart, Bodoky Gyoergy, Barone Carlo et al., 2010. Journal of Clinical Oncology, 28 (3) pp. 466-474.
The effect of translocation-induced nuclear reorganization on gene expression.
Harewood L., Schütz F., Boyle S., Perry P., Delorenzi M., Bickmore W.A., Reymond A., 2010. Genome Research, 20 (5) pp. 554-564. Peer-reviewed.
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models.
Shi L., Campbell G., Jones W.D., Campagne F., Wen Z., Walker S.J., Su Z., Chu T.M., Goodsaid F.M., Pusztai L. et al., 2010. Nature Biotechnology, 28 (8) pp. 827-838. Peer-reviewed.
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer.
Farmer P., Bonnefoi H., Anderle P., Cameron D., Wirapati P., Wirapati P., Becette V., André S., Piccart M., Campone M. et al., 2009. Nature Medicine, 15 (1) pp. 68-74.
FOXC2 and NFATc1 control formation and maturation of collecting lymphatic vessels
Norrmen C., Ivanov K. I., Cheng J., Zangger N., Delorenzi M., Jaquet M., Miura N., Puolakkainen P., Horsley V., Hu J. et al., 2009. pp. 45-45 dans Joint Meeting of the Society for Microcirculation and Vascular Biology Swiss Society for Microcirculation, Journal of Vascular Research. Peer-reviewed.
FOXC2 controls formation and maturation of lymphatic collecting vessels through cooperation with NFATc1.
Norrmén C., Ivanov K.I., Cheng J., Zangger N., Delorenzi M., Jaquet M., Miura N., Puolakkainen P., Horsley V., Hu J. et al., 2009. Journal of Cell Biology, 185 (3) pp. 439-457.
Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia.
Murat A., Migliavacca E., Hussain S.F., Heimberger A.B., Desbaillets I., Hamou M.F., Rüegg C., Stupp R., Delorenzi M., Hegi M.E., 2009. PloS One, 4 (6) pp. e5947. Peer-reviewed.
Non-invasive gene-expression-based detection of well-developed collateral function in individuals with and without coronary artery disease.
Meier P., Antonov J., Zbinden R., Kuhn A., Zbinden S., Gloekler S., Delorenzi M., Jaggi R., Seiler C., 2009. Heart, 95 (11) pp. 900-908.
Phosphorylation modulates FOXC2 transcriptional program by controlling the high-order interaction with DNA.
Ivanov K., Valmu L., Norrmen C., Hajjami H. M.-E., Delorenzi M., Agalarov Y.a.n., Samuilova O., Jaquet M., Miura N., Alitalo K. et al., 2009. pp. 44-44 dans Joint Meeting of the Society for Microcirculation and Vascular Biology/Swiss Society for Microcirculation, Journal of Vascular Research. Peer-reviewed.
Relationship between estrogen receptor alpha location and gene induction reveals the importance of downstream sites and cofactors.
Parisi F., Sonderegger B., Wirapati P., Delorenzi M., Naef F., 2009. BMC Genomics, 10 p. 381. Peer-reviewed.
Selecting control genes for RT-QPCR using public microarray data.
Popovici V., Goldstein D.R., Antonov J., Jaggi R., Delorenzi M., Wirapati P., 2009. Bmc Bioinformatics, 10 p. 42. Peer-reviewed.
An integrated genetic and functional analysis of the role of type II transmembrane serine proteases (TMPRSSs) in hearing loss.
Guipponi M., Toh M.Y., Tan J., Park D., Hanson K., Ballana E., Kwong D., Cannon P.Z., Wu Q., Gout A. et al., 2008. Human Mutation, 29 (1) pp. 130-141. Peer-reviewed.
Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes.
Desmedt C., Haibe-Kains B., Wirapati P., Buyse M., Larsimont D., Bontempi G., Delorenzi M., Piccart M., Sotiriou C., 2008. Clinical Cancer Research, 14 (16) pp. 5158-5165. Peer-reviewed.
Comprehensive spatiotemporal transcriptomic analyses of the ganglionic eminences demonstrate the uniqueness of its caudal subdivision.
Willi-Monnerat S., Migliavacca E., Surdez D., Delorenzi M., Luthi-Carter R., Terskikh A.V., 2008. Molecular and Cellular Neurosciences, 37 (4) pp. 845-856.
Cross-species and cross-platform gene expression studies with the Bioconductor-compliant R package 'annotationTools'.
Kuhn A., Luthi-Carter R., Delorenzi M., 2008. Bmc Bioinformatics, 9 p. 26. Peer-reviewed.
CYR61 and alphaVbeta5 integrin cooperate to promote invasion and metastasis of tumors growing in preirradiated stroma.
Monnier Y., Farmer P., Bieler G., Imaizumi N., Sengstag T., Alghisi G.C., Stehle J.C., Ciarloni L., Andrejevic-Blant S., Moeckli R. et al., 2008. Cancer Research, 68 (18) pp. 7323-7331.
Expression profiling with RNA from formalin-fixed, paraffin-embedded material.
Oberli A., Popovici V., Delorenzi M., Baltzer A., Antonov J., Matthey S., Aebi S., Altermatt H.J., Jaggi R., 2008. Bmc Medical Genomics, 1 p. 9. Peer-reviewed.
MAMOT: hidden Markov modeling tool.
Schütz F., Delorenzi M., 2008. Bioinformatics, 24 (11) pp. 1399-1400. Peer-reviewed.
Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures.
Wirapati P., Sotiriou C., Kunkel S., Farmer P., Pradervand S., Haibe-Kains B., Desmedt C., Ignatiadis M., Sengstag T., Schütz F. et al., 2008. Breast Cancer Research, 10 (4) pp. R65.
Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen.
Loi S., Haibe-Kains B., Desmedt C., Wirapati P., Lallemand F., Tutt A.M., Gillet C., Ellis P., Ryder K., Reid J.F. et al., 2008. Bmc Genomics, 9 p. 239. Peer-reviewed.
Stem cell-related &quot;self-renewal&quot; signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.
Murat A., Migliavacca E., Gorlia T., Lambiv W.L., Shay T., Hamou M.F., de Tribolet N., Regli L., Wick W., Kouwenhoven M.C. et al., 2008. Journal of Clinical Oncology, 26 (18) pp. 3015-3024.
Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma.
Vlassenbroeck I., Califice S., Diserens A.C., Migliavacca E., Straub J., Di Stefano I., Moreau F., Hamou M.F., Renard I., Delorenzi M. et al., 2008. Journal of Molecular Diagnostics, 10 (4) pp. 332-337. Peer-reviewed.
Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood.
Runne H., Kuhn A., Wild E.J., Pratyaksha W., Kristiansen M., Isaacs J.D., Régulier E., Delorenzi M., Tabrizi S.J., Luthi-Carter R., 2007. Proceedings of the National Academy of Sciences of the United States of America, 104 (36) pp. 14424-14429.
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade.
Loi S., Haibe-Kains B., Desmedt C., Lallemand F., Tutt A.M., Gillet C., Ellis P., Harris A., Bergh J., Foekens J.A. et al., 2007. Journal of Clinical Oncology, 25 (10) pp. 1239-1246.
Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome.
Vuaroqueaux V., Urban P., Labuhn M., Delorenzi M., Wirapati P., Benz C.C., Flury R., Dieterich H., Spyratos F., Eppenberger U. et al., 2007. Breast Cancer Research, 9 (3) pp. R33.
MADAP, a flexible clustering tool for the interpretation of one-dimensional genome annotation data.
Schmid C.D., Sengstag T., Bucher P., Delorenzi M., 2007. Nucleic Acids Research, 35 (Web Server issue) pp. W201-W205.
Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage.
Kuhn A., Goldstein D.R., Hodges A., Strand A.D., Sengstag T., Kooperberg C., Becanovic K., Pouladi M.A., Sathasivam K., Cha J.H. et al., 2007. Human Molecular Genetics, 16 (15) pp. 1845-1861.
Natural gene-expression variation in Down syndrome modulates the outcome of gene-dosage imbalance.
Prandini P., Deutsch S., Lyle R., Gagnebin M., Delucinge Vivier C., Delorenzi M., Gehrig C., Descombes P., Sherman S., Dagna Bricarelli F. et al., 2007. American Journal of Human Genetics, 81 (2) pp. 252-263.
Stroma irradiation promotes CYR61/AV integrin-dependent tumour metastasts by suppressing angiogenesis
Monnier Y., Farmer P., Bieler G., Imaizumi N., Senstag T., Alghisi G.C., Stehle J.C., Andrejevic-Blant S., Moeckli R., Goodman S. et al., 2007. p. 276 dans 21th European Congress of Pathology, Virchows Archiv. Peer-reviewed.
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series.
Desmedt C., Piette F., Loi S., Wang Y., Lallemand F., Haibe-Kains B., Viale G., Delorenzi M., Zhang Y., d'Assignies M.S. et al., 2007. Clinical Cancer Research, 13 (11) pp. 3207-3214.
A gene expression signature that distinguishes desmoid tumours from nodular fasciitis.
Bacac M., Migliavacca E., Stehle J.C., McKee T., Delorenzi M., Coindre J.M., Guillou L., Stamenkovic I., 2006. Journal of Pathology, 208 (4) pp. 543-553.
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.
Sotiriou C., Wirapati P., Loi S., Harris A., Fox S., Smeds J., Nordgren H., Farmer P., Praz V., Haibe-Kains B. et al., 2006. Journal of the National Cancer Institute, 98 (4) pp. 262-272.
Gene expression profiling reveals consistent differences between clinical samples of human leukaemias and their model cell lines.
Leupin N., Kuhn A., Hügli B., Grob T.J., Jaggi R., Tobler A., Delorenzi M., Fey M.F., 2006. British Journal of Haematology, 135 (4) pp. 520-523.
HTPSELEX--a database of high-throughput SELEX libraries for transcription factor binding sites.
Jagannathan V., Roulet E., Delorenzi M., Bucher P., 2006. Nucleic Acids Research, 34 (Database issue) pp. D90-D94.
Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
Urban P., Vuaroqueaux V., Labuhn M., Delorenzi M., Wirapati P., Wight E., Senn H.J., Benz C., Eppenberger U., Eppenberger-Castori S., 2006. Journal of Clinical Oncology, 24 (26) pp. 4245-4253.
Mechanisms regulating the proliferative potential of human CD8+ T lymphocytes overexpressing telomerase.
Menzel O., Migliaccio M., Goldstein D.R., Dahoun S., Delorenzi M., Rufer N., 2006. Journal of Immunology, 177 (6) pp. 3657-3668. Peer-reviewed.
Proteomics fingerprinting of phagosome maturation and evidence for the role of a Galpha during uptake.
Gotthardt D., Blancheteau V., Bosserhoff A., Ruppert T., Delorenzi M., Soldati T., 2006. Molecular and Cellular Proteomics, 5 (12) pp. 2228-2243.
Regional and cellular gene expression changes in human Huntington's disease brain.
Hodges A., Strand A.D., Aragaki A.K., Kuhn A., Sengstag T., Hughes G., Elliston L.A., Hartog C., Goldstein D.R., Thu D. et al., 2006. Human Molecular Genetics, 15 (6) pp. 965-977.
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.
Buyse M., Loi S., van't Veer L., Viale G., Delorenzi M., Glas A.M., d'Assignies M.S., Bergh J., Lidereau R., Ellis P. et al., 2006. Journal of the National Cancer Institute, 98 (17) pp. 1183-1192.
An atlas of human gene expression from massively parallel signature sequencing (MPSS).
Jongeneel C.V., Delorenzi M., Iseli C., Zhou D., Haudenschild C.D., Khrebtukova I., Kuznetsov D., Stevenson B.J., Strausberg R.L., Simpson A.J. et al., 2005. Genome research, 15 (7) pp. 1007-14. Peer-reviewed.
Changes in the transcriptional profile of transporters in the intestine along the anterior-posterior and crypt-villus axes.
Anderle P., Sengstag T., Mutch D.M., Rumbo M., Praz V., Mansourian R., Delorenzi M., Williamson G., Roberts M.A., 2005. BMC Genomics, 6 (1) p. 69.
Identification of molecular apocrine breast tumours by microarray analysis.
Farmer P., Bonnefoi H., Becette V., Tubiana-Hulin M., Fumoleau P., Larsimont D., Macgrogan G., Bergh J., Cameron D., Goldstein D. et al., 2005. Oncogene, 24 (29) pp. 4660-4671. Peer-reviewed.
On ubiquitin ligases and cancer.
Beckmann J.S., Maurer F., Delorenzi M., Falquet L., 2005. Human mutation, 25 (6) pp. 507-12.
Ubiquitin ligases as cancer genes
Beckmann J.S., Maurer F., Delorenzi M., Falquet L., 2004/08. Nature Reviews Cancer, 4 pp. Online Correspondence.
The Eukaryotic Promoter Database EPD: the impact of in silico primer extension.
Schmid C.D., Praz V., Delorenzi M., Périer R., Bucher P., 2004. Nucleic Acids Research, 32 (Database issue) pp. D82-D85.
The serine repeat antigen (SERA) gene family phylogeny in Plasmodium: the impact of GC content and reconciliation of gene and species trees.
Bourgon R., Delorenzi M., Sargeant T., Hodder A.N., Crabb B.S., Speed T.P., 2004. Molecular Biology and Evolution, 21 (11) pp. 2161-2171.
Transcript profiling suggests that differential metabolic adaptation of mice to a high fat diet is associated with changes in liver to muscle lipid fluxes.
de Fourmestraux V., Neubauer H., Poussin C., Farmer P., Falquet L., Burcelin R., Delorenzi M., Thorens B., 2004. Journal of Biological Chemistry, 279 (49) pp. 50743-50753. Peer-reviewed.
Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes.
Godard S., Getz G., Delorenzi M., Farmer P., Kobayashi H., Desbaillets I., Nozaki M., Diserens A.C., Hamou M.F., Dietrich P.Y. et al., 2003. Cancer Research, 63 (20) pp. 6613-6625. Peer-reviewed.
Enzymic, phylogenetic, and structural characterization of the unusual papain-like protease domain of Plasmodium falciparum SERA5.
Hodder A.N., Drew D.R., Epa V.C., Delorenzi M., Bourgon R., Miller S.K., Moritz R.L., Frecklington D.F., Simpson R.J., Speed T.P. et al., 2003. Journal of Biological Chemistry, 278 (48) pp. 48169-48177.
Genomic Profiling of Membrane Transporters in the Intestine using Microarrays and GO Ontology.
Anderle P., Sengstag T., Mutch D., Praz V., Fiaux M., Mansiourian R., Delorenzi M., Williamson G., Roberts M., 2003. BioMedical Transporters pp. 3-15.
A subset of Plasmodium falciparum SERA genes are expressed and appear to play an important role in the erythrocytic cycle.
Miller S.K., Good R.T., Drew D.R., Delorenzi M., Sanders P.R., Hodder A.N., Speed T.P., Cowman A.F., de Koning-Ward T.F., Crabb B.S., 2002. Journal of Biological Chemistry, 277 (49) pp. 47524-47532.
An HMM model for coiled-coil domains and a comparison with PSSM-based predictions.
Delorenzi M., Speed T., 2002. Bioinformatics, 18 (4) pp. 617-625.
Genes for glycosylphosphatidylinositol toxin biosynthesis in Plasmodium falciparum.
Delorenzi M., Sexton A., Shams-Eldin H., Schwarz R.T., Speed T., Schofield L., 2002. Infection and Immunity, 70 (8) pp. 4510-4522.
Identification of proteins from Plasmodium falciparum that are homologous to reticulocyte binding proteins in Plasmodium vivax.
Triglia T., Thompson J., Caruana S.R., Delorenzi M., Speed T., Cowman A.F., 2001. Infection and Immunity, 69 (2) pp. 1084-1092.
Expression of Abdominal-B homeoproteins in Drosophila embryos.
Delorenzi M., Bienz M., 1990. Development, 108 (2) pp. 323-329.
Drosophila homoeotic genes encode transcriptional activators similar to mammalian OTF-2.
Thali M., Müller M.M., DeLorenzi M., Matthias P., Bienz M., 1988. Nature, 336 (6199) pp. 598-601.
Evidence that the Abdominal-B r element function is conferred by a trans-regulatory homeoprotein.
Delorenzi M., Ali N., Saari G., Henry C., Wilcox M., Bienz M., 1988. EMBO Journal, 7 (10) pp. 3223-3231.
Analysis of a sea urchin gene cluster coding for the small nuclear U7 RNA, a rare RNA species implicated in the 3' editing of histone precursor mRNAs.
Delorenzi M., Rohrer U., Birnstiel M.L., 1986. Proceedings of the National Academy of Sciences of the United States of America, 83 (10) pp. 3243-3247.
Unicentre - CH-1015 Lausanne
Tél. +41 21 692 11 11
Fax. +41 21 692 26 15
Swiss University